
    
      Non -inferiority in 8-month Major Adverse Cardiac Events (MACE) and in-segment late lumen
      loss at 9 months between the CoStar™ Paclitaxel-Eluting Coronary Stent System and the TAXUS™
      Express2™ Drug Eluting Coronary Stent System for the treatment of a single de novo lesion per
      vessel in patients with single and multi-vessel coronary disease.
    
  